QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.14

AMENDED AND RESTATED TECHNOLOGY ACQUISITION AGREEMENT

        This Amended and Restated Technology Acquisition Agreement (the
"Agreement") is entered into effective as of the 14th day of March, 1996, by and
between Nicholas Kowanko, Ph.D. of 618 South Fifth Street, Moorhead,
Minnesota 56560 ("Dr. Kowanko") and CryoLife, Inc. of 2211 New Market Parkway,
Suite 142, Marietta, Georgia 30067 ("CryoLife").

        WHEREAS, Dr. Kowanko has invented and may develop in the future,
pursuant to his services under this Agreement, certain Trade Secrets, Know-How
and Patents (as defined below and collectively referred to as the "Technology")
related to methods, procedures, and sciences for creating a bioadhesive
("Adhesive") which is more particularly described in Exhibit A attached hereto;

        WHEREAS, Dr. Kowanko is the owner of all right, title, and interest in
and to the Technology;

        WHEREAS, CryoLife desires to acquire the Technology in order to continue
its product development and eventually commercialize products utilizing the
Technology and to obtain certain assistance from Dr. Kowanko;

        WHEREAS, the parties entered into a Technology Acquisition Agreement
(the "TA Agreement") on March 14, 1996 to transfer the Technology and provide
for Dr. Kowanko's assistance upon the terms and conditions set forth therein;
and

        WHEREAS, the parties desire to amend the TA Agreement in certain
particulars by entering into this Agreement, which Agreement the parties intend
to supersede the original TA Agreement.

        NOW, THEREFORE, in consideration of the premises, the promises
hereinafter set forth, and other valuable consideration the receipt and
sufficiency of which are hereby acknowledged, the parties agree as follows:

        I.    Definitions.    The following terms shall have the following
meanings when used in this Agreement:

        A.    "Improvements" shall mean any and all (i) changes or enhancements
to the Adhesive (including, without limitation, formulation changes to reduce
Adhesive and component toxicity), (ii) new bioadhesive inventions, and
(iii) information relating to any delivery devices for the Adhesive, developed
by Dr. Kowanko pursuant to his services under this Agreement.

        B.    "Know-How" shall mean any and all non-confidential information
relating to the Adhesive or its formulation currently owned by Dr. Kowanko or
developed by Dr. Kowanko pursuant to his services under this Agreement.

        C.    "Patent(s)" shall mean any and all domestic and foreign patents or
patent applications of Dr. Kowanko, which relates to the Adhesive or its
formulation, or which may in the future be filed on the Trade Secrets or
Know-How, including, without limitation, U.S. Patent No. 5385606. The term
Patent(s) also shall include any and all U.S. or foreign divisions,
continuations, continuation-in-part, substitutions, reissues, and extensions of
said Patent(s).

        D.    "Technology" shall mean the Know-How, Patent(s), Trade Secrets,
and Improvements.

        E.    "Trade Secrets" shall mean any and all confidential information,
relating to the Adhesive or its formulation currently owned by Dr. Kowanko or
developed by Dr. Kowanko pursuant to his services under this Agreement.

        II.    Assignment of Technology.    Dr. Kowanko hereby sells, assigns,
and transfers, and agrees to sell, assign, and transfer all of his right, title,
and interest in and to the Technology to CryoLife. Dr. Kowanko agrees to execute
such further documents and instruments as CryoLife may reasonably request in
order to further evidence the transfer of the Technology as contemplated
hereunder.

--------------------------------------------------------------------------------

        III.    Purchase Price.    

        A.    Purchase Price.    CryoLife shall pay Dr. Kowanko the sum of
$1,200,000 (the "Purchase Price") for the assignment of the Technology. The
Purchase Price shall be payable as follows: $290,000 shall be payable upon
execution of this Agreement (which amount has been paid) and the balance shall
be payable (i) in three equal installments of $290,000 each of the first,
second, and third anniversaries of the date of this Agreement and (ii) one final
installment of $40,000 on the fourth anniversary of the date of this Agreement.
The Purchase Price shall also include a 1.7% royalty on Net Revenues (gross
revenues minus sales tax, returns, discounts, freight and return freight, if
any) from future commercial sales of the Adhesive by CryoLife which exceed
$25 million in the aggregate. In the case where the right to sell Adhesive is
licensed to a third party, the royalty rate shall be computed, at CryoLife's
discretion, as 1.7% of the Net Revenues of the licensee from commercial sales of
the Adhesive or as 10% of CryoLife's revenues from the licensee (in which later
event, CryoLife will not be obliged to pay a 1.7% royalty based on its
licensee's sales of Adhesives). The first payment of royalties shall be due
within 90 days after the end of the calendar year in which CryoLife first
generates revenues from the Adhesive in excess of $25 million in the aggregate
and shall be accompanied by a written report showing all Net Revenues and
royalties accrued during the preceding calendar year. Royalty payments and
written reports shall be made and furnished annually thereafter. Notwithstanding
the foregoing, the royalty portion of the Purchase Price shall not be payable at
any time after, if ever, the Patents expire or are declared invalid by a court
of law and such judgment is not overruled. If CryoLife chooses to license the
Adhesive to a third party for a lump sum or fixed payment (as opposed to a
royalty) before an aggregate of $25 million in commercial sales has been
reached, it must condition sub-licensing on accurate accounting by the licensee
on an annual basis of all net revenues received from sales of the Adhesive.
CryoLife must add these accounting figures to all sales from other sources for
purposes of computing aggregate sales and the computation of amounts owed to
Dr. Kowanko.

        B.    Consulting Fee.    For so long as Dr. Kowanko provides consulting
services pursuant to Section 9 below, Dr. Kowanko shall receive a consulting fee
of $10,000 per year. Such consulting fee shall be payable each year in advance.

        C.    Records.    CryoLife shall maintain a true and correct set of
records pertaining to commercial sales of Adhesive and license revenues obtained
from the licenses of the Adhesive. CryoLife shall be obliged to maintain records
relating to any year for a period of five years. CryoLife agrees to permit an
auditor selected by Dr. Kowanko and reasonably acceptable to CryoLife to have
access during normal business hours to such records to determine the correctness
of any report and/or royalty payment made under this Agreement. In the event
that the audit reveals an underpayment of royalty by more than 7%, the cost of
the audit shall be paid by CryoLife. Such accountant shall maintain in
confidence, and shall not report to Dr. Kowanko or others, any information
concerning CryoLife or its operations or properties other than information
directly relating to the correctness of such reports and payments.

        IV.    Representations of Dr. Kowanko.    Dr. Kowanko hereby represents
and warrants that he independently developed the Technology, that no university
or governmental agency with or for whom Dr. Kowanko works or has worked in the
past, or any student or employee thereof (other than Dr. Kowanko), has any
right, title or interest in or to the Technology, and that Dr. Kowanko has the
authority to enter into and perform his obligations under this Agreement.
Dr. Kowanko further represents and warrants that he knows of no other compound
or adhesive similar to the Adhesive or which provides the same or substantially
similar functionality. Dr. Kowanko warrants that said Technology has not been
assigned, licensed, pledged, mortgaged or conveyed in whole or in part to any
third party. Dr. Kowanko warrants that he has no agreement with any third party
which conflicts with his obligations to CryoLife under this Agreement.
Dr. Kowanko does not warrant that the practice of the Patent or the use by
CryoLife of the Technology does not infringe or impinge upon any patent rights
of others.

--------------------------------------------------------------------------------

        V.    Indemnification.    Subject to the accuracy of the representations
and warranties of Dr. Kowanko set forth elsewhere in this Agreement and the
provisions of Section 6 below, CryoLife shall indemnify, defend, and hold
Dr. Kowanko harmless from and against any and all damages, liability, losses,
and expenses incurred by Dr. Kowanko arising our of any claim, lawsuit, action
or proceeding (collectively, "Claim") against Dr. Kowanko by a third party based
upon the production, distribution, or marketing by CryoLife of the Technology.
As between the parties hereto, CryoLife shall defend, settle, or compromise all
litigation (including action, suits and proceedings before judicial or
administrative tribunals, and arbitration proceedings), in which CryoLife, or
its vendees, are charged by virtue of the manufacture, use or sale of Products
or the use of the Technology under this Agreement with infringement of any
patent held by any third party.

        VI.    Liability.    

        A.    Infringement; Misappropriation.    Dr. Kowanko warrants that he
has received no notice that the manufacture, use, or sale of any Products or the
use of Technology is an infringement or misappropriation of the right of any
third party and that to the best of his knowledge and belief, the manufacture,
use, or sale of Products or the use of the Technology is not an infringement or
misappropriation of the rights of any third party. In the event CryoLife is
obliged to defend any action for such infringement or misappropriation of any
patents held by any third party, Dr. Kowanko shall provide such assistance,
including the furnishing of documents and information and the execution of all
necessary documents as CryoLife may reasonably require, but under no
circumstances does Dr. Kowanko warrant or guarantee that the Products or the
Technology is not or will not be in infringement or misappropriation of any
patent rights of any third party. No monies received by Dr. Kowanko from
CryoLife shall be returned to CryoLife in the event of a third party suit,
whether or not it is successful. Dr. Kowanko does not warrant or represent that
the Products or the Technology is free of infringement of any patent that may be
existent at any time and Dr. Kowanko does not offer or extend any indemnity for
infringement of any patent, including those which may at any time be in
existence at a place of business of CryoLife or the place of manufacture of the
Products.

        B.    Disclaimer of Liability.    In no event shall Dr. Kowanko be
liable for: (a) special, indirect, incidental or consequential damages, or
(b) any damages whatsoever resulting from the loss of use, data or profits
arising out of or in connection with this Agreement or the use or performance of
any Technology, whether in an action based on contract or tort, including
negligence. Dr. Kowanko shall not be liable for property damage or personal
injury, including death, resulting from the act done or not done in connection
with an obligation assumed by either Dr. Kowanko or CryoLife hereunder other
than an act done or not done as a result of willful wrongdoing or negligence of
Dr. Kowanko as determined by a court of law.

        VII.    Prevention of Infringement.    Dr. Kowanko will assist CryoLife
in connection with any actions by CryoLife to prevent or stop any infringement
or misappropriation by others of the Technology. CryoLife shall reimburse
Dr. Kowanko for Dr. Kowanko's necessary and reasonable out-of-pocket costs
incurred in cooperating with Cryolife, at CryoLife's request, with respect to
litigation hereunder.

        VIII.    Confidentiality.    Dr. Kowanko shall keep confidential and
shall not disclose or otherwise permit access to the Trade Secrets to any other
entity without CryoLife's prior written approval and will limited access to
Know-How to the extent reasonably possible. Dr. Kowanko agrees to submit to
CryoLife's publications review committee any articles or writings he proposes to
publish and to permit the committee a reasonable period of time consistent with
its general practices to review such material and to require deletions of
confidential or proprietary information prior to publication or to delay
publication up to nine months for the convenience of CryoLife. Dr. Kowanko may,
if he chooses, become a member of the committee as part of his consulting
services to CryoLife. If Dr. Kowanko disagrees as to whether material is
confidential or proprietary so as to permit the committee to require its
deletion from publishable material, Dr. Kowanko may submit his disagreement to
arbitration conducted by two qualified scientists, one each selected by
Dr. Kowanko and CryoLife, for resolution. Unless the parties agree to other
procedures, the arbitration will be conducted in accordance with the

--------------------------------------------------------------------------------

rules of the American Arbitration Association. Each party shall bear its own
costs associated with arbitration.

        IX.    Consulting Services.    Dr. Kowanko shall provide consulting
services to CryoLife for a period of five years following the date of this
Agreement on those projects described in (a) that certain letter dated
October 6, 1995 from Dr. Kowanko to April L. O'Hara at CryoLife and (b) that
certain letter dated October 6, 1995 from Dr. Kowanko to Dr. Brenda Smith Morse
at CryoLife, copies of each of which are attached hereto as Exhibit B, and on
such other projects as may be proposed by Dr. Kowanko and approved by CryoLife.
Dr. Kowanko shall devote sufficient time and attention to the performance of
services hereunder to complete the projects agreed to by CryoLife and
Dr. Kowanko within such time frames as CryoLife may reasonably assign. After the
initial five-year period, Dr. Kowanko agrees to continue to provide consulting
services to CryoLife pursuant to this Section 9 on a year to year basis,
provided (1) neither Dr. Kowanko nor CryoLife has notified the other in writing
at least 60 days prior to the end of the then current consulting term and
(ii) the parties have agreed upon a consulting fee to be payable for
Dr. Kowanko's services during the extended term.

        X.    Patent Responsibilities.    CryoLife shall have the sole right, at
its sole cost and expense, to take any action in connection with the
preparation, filing, and maintenance of any patents and patent applications,
including any continuations, continuations-in-part, substitutions, reissues, and
extensions thereof, with respect to the Technology. Dr. Kowanko shall assist
CryoLife, at CryoLife's cost and expense, in connection with any such efforts.

        XI.    General Provisions.    

        A.    Entire Agreement.    This Agreement constitutes the entire
agreement and understanding of the parties with respect to the Technology and
supersedes and terminates all other prior commitments, arrangements, or
understandings, both oral and written between the parties with respect to the
Technology, including, without limitation, the Technology Investigation and
Option Agreement dated June 15, 1993 between the parties and the TA Agreement.

        B.    Modification.    This Agreement may not be modified or amended
except by an instrument in writing executed by each of the parties.

        C.    Binding.    This Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns.

        D.    Governing Law.    This Agreement shall be governed and construed
in accordance with the laws of the State of Georgia.

        E.    Notices.    Any notices or other communications required or
permitted hereunder shall be in writing and shall be sent by (a) personal
delivery (including delivery by Federal Express or similar overnight courier),
(b) mailed by registered or certified mail, return receipt requested, postage
prepaid, or (c) transmitted by facsimile, telex, or telecopy to the numbers set
forth below and with originals of such transmissions sent by registered or
certified mail. Notices shall be sent to the addresses as set forth below or to
such other addresses as may be hereafter furnished by one party to the other
party in compliance with the terms, hereof.

  If to Dr. Kowanko: at the address set forth for Dr. Kowanko
in the first paragraph of this Agreement
 
If to CryoLife:
at the address set forth for CryoLife
in the first paragraph of this Agreement

Notices shall be effective (a) upon receipt by the addressee, if sent by
personal delivery or mail, or (b) upon transmission, if sent by telecopy, telex,
or facsimile.

--------------------------------------------------------------------------------

        F.    Waiver.    None of the provisions of the Agreement shall be deemed
to have been waived by any act or acquiescence on the part of either party,
their agents or employees, but may be waived only by instruments in writing
signed by an authorized officer of the respective party. No waiver of any
provision of this Agreement shall constitute a waiver of any other provision or
of the same provisions on another occasion.

        G.    Counterparts.    This Agreement may be executed simultaneously in
two or more counterparts, each of which shall be deemed an original an all of
which together shall constitute but one and the same instrument.

        IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date set forth herein by their duly authorized
representatives.

Sworn to and subscribed before me
the      day of                , 1996.
 
 
 
 
 
 
 
 
  

--------------------------------------------------------------------------------

  

--------------------------------------------------------------------------------

Notary Public
 
 
  

--------------------------------------------------------------------------------

NICHOLAS KOWANKO, Ph.D.
(Notarial Seal)
 
 
  My commission expires:   

--------------------------------------------------------------------------------

     
Sworn to and subscribed before me
the 8th day of August, 1996.
 
CRYOLIFE, INC.
/s/  SUZANNE K. GABBERT      

--------------------------------------------------------------------------------

 
By:
[Illegible]

--------------------------------------------------------------------------------

Suzanne K. Gabbert

--------------------------------------------------------------------------------

Notary Public   Title: President/CEO

--------------------------------------------------------------------------------

(Notarial Seal)
My commission expires:
Notary Public, Cobb County, Georgia
My Commission Expires
Sept. 13, 1996.

--------------------------------------------------------------------------------

 
 
 

--------------------------------------------------------------------------------

        F.    Waiver.    None of the provisions of the Agreement shall be deemed
to have been waived by any act or acquiescence on the part of either party,
their agents or employees, but may be waived only by instruments in writing
signed by an authorized officer of the respective party. No waiver of any
provision of this Agreement shall constitute a waiver of any other provision or
of the same provisions on another occasion.

        G.    Counterparts.    This Agreement may be executed simultaneously in
two or more counterparts, each of which shall be deemed an original an all of
which together shall constitute but one and the same instrument.

        IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date set forth herein by their duly authorized
representatives.

Sworn to and subscribed before me
the 24th day of July, 1996.
 
 
 
 
 
 
 
 
/s/  GAIL L. SMITH      

--------------------------------------------------------------------------------

  

--------------------------------------------------------------------------------

Notary Public
 
 
/s/  NICHOLAS KOWANKO      

--------------------------------------------------------------------------------

NICHOLAS KOWANKO, Ph.D.
(Notarial Seal)
My commission expires:
GAIL L. SMITH
Notary Public, STATE OF NORTH DAKOTA
My Commission Expires
FEB 26, 2002

--------------------------------------------------------------------------------

 
 
 
Sworn to and subscribed before me
the      day of                , 1996.
 
CRYOLIFE, INC.
  

--------------------------------------------------------------------------------

 
By:
  

--------------------------------------------------------------------------------

  

--------------------------------------------------------------------------------

Notary Public   Title:   

--------------------------------------------------------------------------------

(Notarial Seal)
My commission expires:
  

--------------------------------------------------------------------------------

 
 
 

--------------------------------------------------------------------------------

EXHIBIT A

Definition of Adhesive

        An adhesive composition, primarily intended as tissue adhesive, comprise
of dialdehydes and proteinaceous material, and methods for its use. The adhesive
property is gained primarily by chemical reaction of these components with each
other. "Adhesive" includes all inventions described in the Patents, which the
parties acknowledge include all those patents and patent applications described
on the attached Nicholas Kowanko Patent Inventory dated March 13, 1996.

--------------------------------------------------------------------------------

QuickLinks

AMENDED AND RESTATED TECHNOLOGY ACQUISITION AGREEMENT